GlobalData has
released its new Country report, PharmaPoint: Meningococcal Vaccines France
Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute
infection caused by the gram-negative bacterium Neisseria meningitidis. Its
rapid onset and severity of symptoms makes prompt and effective diagnosis and
treatment nearly impossible. For these reasons the meningococcal disease space
is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as
Sanofis Menactra and Novartis Menveo, account for the vast majority of global
sales, with the US adolescent market being the key target segment. GlobalData
expects growth in the meningococcal vaccines market to be primarily driven by
the launch of serotype B vaccines, which address a critical unmet need in the
treatment landscape. Vaccines that better protect infants and/or provide a longer
duration of immunity also have an opportunity to seize market share during
2012-2022.
To
Read The Complete Report with TOC :-
GlobalData does
not expect relative patient share to change within the MenC conjugate space
because Nuron Biotechs Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C
all possess similar clinical profiles and price points. The MenC conjugate
patient share is largely determined by prescriber preference in France and
therefore is not expected to change drastically during the forecast period. The
French government has expressed disappointment with the low coverage rates of
its MenC immunization program and is expected to renew efforts to expand
vaccine use (Stahl et al., 2013). In general, the sales potential in France is
derived from the immunization recommendations, which largely determine vaccine
usage.
Scope
- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting France Meningococcal Vaccines market.
To Buy a Copy Of This Report:-
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in France
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment